Bharat Parenterals Ltd
Bharat Parenterals Ltd. is a Gujarat based pharmaceutical company producing general and B-lactum group of drugs as well as antiretroviral drugs. [1]
- Market Cap ₹ 766 Cr.
- Current Price ₹ 1,326
- High / Low ₹ 1,465 / 321
- Stock P/E 49.9
- Book Value ₹ 337
- Dividend Yield 0.06 %
- ROCE 11.3 %
- ROE 9.01 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 9.80% over past five years.
- Company has a low return on equity of 12.4% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 0.88% of profits over last 3 years
- Company has high debtors of 188 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|
124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 241 | |
114 | 105 | 124 | 191 | 200 | 179 | 183 | 198 | 213 | |
Operating Profit | 10 | 7 | 12 | 29 | 28 | 25 | 29 | 20 | 28 |
OPM % | 8% | 6% | 9% | 13% | 12% | 12% | 14% | 9% | 11% |
5 | 8 | 7 | 13 | 11 | 9 | 7 | 12 | 6 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
Depreciation | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 7 |
Profit before tax | 9 | 7 | 13 | 35 | 33 | 27 | 28 | 24 | 24 |
Tax % | 31% | 8% | 29% | 39% | 26% | 25% | 25% | 33% | |
6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | 15 | |
EPS in Rs | 11.26 | 12.03 | 15.92 | 37.09 | 42.13 | 35.59 | 36.45 | 28.47 | 29.98 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | -2% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | -14% |
TTM: | -12% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 44% |
3 Years: | 55% |
1 Year: | 294% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 12% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 51 | 58 | 67 | 88 | 112 | 138 | 160 | 177 | 189 |
19 | 6 | 9 | 5 | 1 | 12 | 18 | 50 | 100 | |
44 | 40 | 50 | 60 | 68 | 43 | 42 | 118 | 134 | |
Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 429 |
35 | 31 | 34 | 35 | 33 | 45 | 41 | 42 | 51 | |
CWIP | 0 | 0 | 0 | 1 | 12 | 0 | 26 | 99 | 141 |
Investments | 0 | 1 | 1 | 1 | 0 | 43 | 11 | 0 | 0 |
85 | 79 | 98 | 121 | 142 | 111 | 148 | 209 | 236 | |
Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 429 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
0 | -2 | 6 | 20 | 14 | 24 | -1 | 22 | |
0 | -2 | -8 | -9 | -13 | -43 | -7 | -78 | |
0 | -8 | 4 | -4 | -3 | 10 | 9 | 61 | |
Net Cash Flow | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 |
Inventory Days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 |
Days Payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 155 |
Cash Conversion Cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 134 |
Working Capital Days | 45 | 64 | 92 | 76 | 89 | 112 | 157 | 156 |
ROCE % | 11% | 18% | 39% | 31% | 20% | 17% |
Documents
Announcements
- Compliance Certificate For The Year Ended On 31St March, 2024 Certifying That All Certificates Are Issued Within 30Days Of Date Of Lodgment Of Transfer, Transimission, Sub-Division, Cosolidation Etc 4m
-
Compliances-Compliance Certificate For The Period Ended March, 2024.
13 Apr - Compliance Certificate for the year ended on 31st March, 2024 related to share transfer facility.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Depositories and Participants) Regulations, 2018 for period ended on 31st March, 2024.
- Closure of Trading Window 30 Mar
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
28 Mar - Additional Details required for corporate Announcement filed with SEBI for Announcement of Resignation of Company Secretary /Compliance officer filled as on 2nd October, 2023. For …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2003
from bse
-
Financial Year 2002
from bse
-
Financial Year 1999
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
Product Portfolio
The Co has a portfolio of over 500 formulations. It produces pharmaceuticals across categories such as B-LACTAM Antibiotics, Anti Retroviral, Cephalosporins Antibiotics, Antiprotozoal / Anthelmintic Respiratory, Antiallergic, Cleansing Agents /Skin Infections, Cardiovascular System, Anti Diabitic, Anti Fungal etc. [1]